Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)

The Phase 3 THRIVE-AA1 trial assessed the efficacy and safety of deuruxolitinib, a JAK1/JAK2 inhibitor, in 706 adults with alopecia areata experiencing significant hair loss. Participants received either 8 mg or 12 mg of deuruxolitinib twice daily, or a placebo, for 24 weeks. Results indicated that 29.6% of patients on 8 mg and 41.5% on 12 mg achieved a SALT score ≤20, compared to 0.8% in the placebo group, demonstrating significant hair regrowth. Patient satisfaction with hair regrowth was notably higher in the treatment groups. Most adverse events were mild or moderate, with serious events being rare and no deaths reported. The study concluded that deuruxolitinib is effective for hair regrowth in alopecia areata and is generally well tolerated, though further research is needed to evaluate long-term safety and efficacy.